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The potential therapy for hematological malignancies
is allogeneic hematopoietic cell transplantation (HCT). It has
been shown that stronger graft-versus-leukemia/lymphoma
(GvL) effects occur in the presence of stronger graft-versus-
host (GvH) alloreactivity associated with extensive MHC
mismatches.1-3 Acute degrees (II-IV) of graft-versus-host
disease (GVHD) are observed in 25-60% of HLA-identical
related-donor HCT and in 45-70% of matched unrelated
transplant recipients4-6 and this remains the major cause of
morbidity and mortality in patients undergoing allogeneic
bone marrow transplantation.7,8 The usual immunosuppressive
drugs such as cyclosporine A, prednisone, and methotrexate9-
11 have not successfully eliminated GvHD.
FTY720 is a synthetic compound based on the
metabolite of ascomycete Isaria sinclairii which has shown
GvHD-inhibitory activity when rat spleen cells were
transplanted from a parental strain into F1 rats treated with
200 mg/kg cyclophosphamide12 and in a rat small-bowel
transplant model.13  Kim et al.14 showed that lethally irradiated
mice reconstituted with allogeneic BMCs plus spleen cells
and treated with FTY720 (3 mg/kg/day) presented a decrease
in the mortality rate besides reduced clinical GvHD. The group
also observed that GvL effects after the administration of
leukemia/lymphoma T cell line were not impaired in mice
receiving BMCs plus spleen and treated with FTY720.
These encouraging results suggest the possible use of
FTY720 in hematopoietic cell transplantation. In order to
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contribute to the better understanding of FTY720 mechanisms
of action as a monotherapy or in association with tacrolimus,
Lopes et al. show in this issue the results from the experi-
mental model of skin transplantation. FTY720 alone (1 mg/
kg/day) or in combination with tacrolimus (2 mg/kg/day)
during 21 days was associated with improved skin allograft
survival in incompatible mice. Spleen and blood lymphocytes
presented reduced numbers in mice treated with FTY720 alone
and FTY720 + tacrolimus. The CD4+T expression in
splenocytes was also reduced. Activation markers such as
MHC II and ICAM-1 were less expressed in splenocytes from
mice treated with FTY720. Skin graft infiltration was similar in
non-treated and treated groups. In this model, the association
with tacrolimus caused no improvement in the results
observed in mice treated only with FTY720 suggesting that
the FTY720 + tacrolimus combination was not synergistic
and, on considering the side effects of calcineurin inhibitors,
should not be used. On the other hand, the same group15
recently showed that in mice FTY720 + tacrolimus caused
less nephrotoxicity than Tacrolimus alone. Therefore the
combination may be considered in cases of established renal
toxicity as FTY720 seems to protect from the side effects
caused by tacrolimus. These findings have an important
clinical significance as the conditioning regimen (irradiation,
chemotherapy + cytotoxic drugs) and CNIs amongst others
are causative factors of nephropathy after HCT.16
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